{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T16:52:34Z","timestamp":1784307154956,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ard.2025.07.010","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T14:44:29Z","timestamp":1754405069000},"page":"1632-1640","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis"],"prefix":"10.1016","volume":"84","author":[{"given":"Andreas","family":"Kerschbaumer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3056-7664","authenticated-orcid":false,"given":"Marlene","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Pruckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0683-0801","authenticated-orcid":false,"given":"Brigitte","family":"Wildner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Maad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef S.","family":"Smolen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Aletaha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ard.2025.07.010_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0002","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1002\/art.22193","article-title":"Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials","volume":"54","author":"Zink","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ard.2025.07.010_bib0003","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/acr.22860","article-title":"Generalizability of patients with rheumatoid arthritis in biologic agent clinical trials","volume":"68","author":"Vashisht","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ard.2025.07.010_bib0004","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","article-title":"Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis","volume":"344","author":"Elliott","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.07.010_bib0005","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ard.2025.07.010_bib0006","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.07.010_bib0007","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.07.010_bib0008","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ard.2025.07.010_bib0009","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1136\/annrheumdis-2020-219214","article-title":"Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial","volume":"80","author":"Combe","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0010","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1136\/ard-2023-224449","article-title":"Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)","volume":"82","author":"Taylor","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0011","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1056\/NEJMoa2201302","article-title":"Olokizumab versus placebo or adalimumab in rheumatoid arthritis","volume":"387","author":"Smolen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ard.2025.07.010_bib0012","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1136\/annrheumdis-2012-202603","article-title":"Inequities in access to biologic and synthetic DMARDs across 46 European countries","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0013","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","article-title":"Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry","volume":"77","author":"Bergstra","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0014","series-title":"Measuring disparities in health status and in access and use of health care in OECD countries","author":"de Looper","year":"2009"},{"key":"10.1016\/j.ard.2025.07.010_bib0015","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/annrheumdis-2021-221807","article-title":"Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis","volume":"81","author":"Kerschbaumer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0016","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3899\/jrheum.190008","article-title":"Placebo response in rheumatoid arthritis clinical trials","volume":"47","author":"Bechman","year":"2020","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ard.2025.07.010_bib0017","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40261-020-00887-6","article-title":"Factors influencing placebo responses in rheumatoid arthritis clinical trials: a meta-analysis of randomized, double-blind, placebo-controlled studies","volume":"40","author":"Nagai","year":"2020","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.ard.2025.07.010_bib0018","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1136\/ard-2023-224477","article-title":"Aletaha D. Determination of the most appropriate ACR response definition for contemporary drug approval trials in rheumatoid arthritis","volume":"83","author":"Konzett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0019","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/ard.2008.099010","article-title":"Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study","volume":"68","author":"Keystone","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0020","volume":"2022","year":"2023"},{"key":"10.1016\/j.ard.2025.07.010_bib0021","unstructured":"UNDP, Human Development Report 1990 (New York: Oxford University Press), 1990."},{"key":"10.1016\/j.ard.2025.07.010_bib0022","first-page":"36","article-title":"Conducting Meta-Analyses in R with the metafor Package","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.ard.2025.07.010_bib0023","series-title":"R: A Language and Environment for Statistical Computing","year":"2024"},{"key":"10.1016\/j.ard.2025.07.010_bib0024","article-title":"Global recruiting patterns affect placebo response rates in clinical trials of psoriatic arthritis and plaque psoriasis","author":"Kerschbaumer","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ard.2025.07.010_bib0025","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1136\/annrheumdis-2013-203819","article-title":"Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country\u2019s wealth?","volume":"73","author":"Putrik","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0026","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1136\/ard.2009.109983","article-title":"Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database","volume":"68","author":"Sokka","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.07.010_bib0027","article-title":"Beyond GDP measuring what counts for economic and social performance","author":"Jean-Paul","year":"2018","journal-title":"OECD Publishing"},{"key":"10.1016\/j.ard.2025.07.010_bib0028","series-title":"Human Development Report 2021-22: Uncertain Times, Unsettled Lives: Shaping our Future in a Transforming World","year":"2022"},{"key":"10.1016\/j.ard.2025.07.010_bib0029","unstructured":"WHO. Out-of-pocket expenditure as percentage of current health expenditure (CHE) (%). Accessed 6 March 2024. https:\/\/www.who.int\/data\/gho\/data\/indicators\/indicator-details\/GHO\/out-of-pocket-expenditure-as-percentage-of-current-health-expenditure-(che)-(-)"},{"key":"10.1016\/j.ard.2025.07.010_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OARRR.S493457","article-title":"Health disparities in rheumatology in the United States","volume":"17","author":"Wright","year":"2025","journal-title":"Open Access Rheumatol"},{"key":"10.1016\/j.ard.2025.07.010_bib0031","doi-asserted-by":"crossref","first-page":"4972","DOI":"10.1093\/rheumatology\/keab464","article-title":"Targeted literature review of current treatments and unmet need in moderate rheumatoid arthritis in the United Kingdom","volume":"60","author":"Taylor","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.07.010_bib0032","first-page":"S24","article-title":"Measuring methotrexate polyglutamates","volume":"28","author":"Goodman","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ard.2025.07.010_bib0033","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1136\/ard-2022-223413","article-title":"American College of Rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"82","author":"Studenic","year":"2023","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725042438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725042438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T08:00:31Z","timestamp":1777190431000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725042438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0003496725042438"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.07.010","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Global recruitment patterns and placebo responses in clinical trials of rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}